Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 74

Results For "gene"

3080 News Found

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
Drug Approval | November 20, 2024

Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules

The product will be manufactured at Lupin’s Somerset facility in the US


Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


DKSH and Abcam join forces to advance life science research in Vietnam
Supply Chain | November 19, 2024

DKSH and Abcam join forces to advance life science research in Vietnam

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market


Zota Health Care Q2 FY25 revenue up 48.6%
News | November 16, 2024

Zota Health Care Q2 FY25 revenue up 48.6%

Gross Profit stood at Rs. 36.02 crore compared to Rs. 20.42 crore during Q2FY24, a significant increase of 76.40%


Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development
People | November 16, 2024

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University


Solvay and Pantys join forces to advance menstrual health and sustainability
Healthcare | November 15, 2024

Solvay and Pantys join forces to advance menstrual health and sustainability

Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility


NABH integrates FOGSI’S maternal health standards across its certification programs
News | November 15, 2024

NABH integrates FOGSI’S maternal health standards across its certification programs

The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs


AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US
News | November 14, 2024

AstraZeneca invests US$ 3.5 billion in R&D and manufacturing in US

This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs


Hikal Q2 FY25 revenue stood at Rs. 453 Cr
News | November 13, 2024

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%